COVID-19 and Clinical Trials

The CRI Anna-Maria Kellen Clinical Accelerator published our first analysis on the impact of COVID-19 on oncology clinical trials in May 2020. We recently performed a one-year review of the impact that is now available to the larger scientific community. Our aim is to inform the cancer research community of challenges, risks, and contingencies through these updated analyses and publications.

Clinical Trials Stopped Due to COVID-19

In order to continue monitoring the pandemic, we compiled all clinical trials stopped due to COVID-19 below using ClinicalTrials.gov.

COVID-19 and Clinical Trials

While some clinical trials have reported stopping due to COVID-19, more have emerged to treat patients with COVID-19. We have compiled all clinical trials from ClinicalTrials.gov where COVID-19 was mentioned as the condition for enrollment.

Timeline of non-PD-1/PD-L1 Immuno-Oncology Agent Approvals by the FDA

Clinical Trial Analysis Publications

• COVID-19 impact on oncology clinical trials: a 1-year analysis
  Nature Reviews Drug Discovery, May 17, 2021 
• Impact of COVID-19 on oncology clinical trials
  Nature Reviews Drug Discovery, May 18, 2020 

Data Sources: Cancer Research Institute (CRI) analytics derive from public data sources, including trade news, company press releases, academic publications, FDA announcements, clinicaltrials.gov, and conference reports, and proprietary data sources including, but not limited to, GlobalData. The analytical algorithm and visualizations are developed by and therefore sole property of Cancer Research Institute.

Subscribe to our email newsletter to receive the latest updates on our landscape analyses.

Do you want more information on the Clinical Accelerator? Contact us. 

IO Landscapes

Immuno-Oncology Landscape

Cancer Cell Therapy Landscape

PD-1/PD-L1 Immune Checkpoint Inhibitors Landscape

Pancreatic Cancer IO Landscape

Regulatory Approval Timeline of Active Immunotherapies

COVID-19 and Clinical Trials